Home / Resource Library / Alectinib for relapsed or refractory ALK-positive anaplastic large cell lymphoma: an open label phase 2 trial

Alectinib for relapsed or refractory ALK-positive anaplastic large cell lymphoma: an open label phase 2 trial

Results of a phase II study examining Alectinib for treatment of relapsed anaplastic large cell lymphoma.